White blood cell activating adsorber

Abstract

The utility model discloses an activated white blood cell adsorber, which comprises end covers, a shell, an adsorption film and a core rod, the end covers are connected with two ends of the shell to form a closed cavity, the adsorption film is positioned in the closed cavity, and the end covers at two ends are respectively provided with a blood flow inlet and a blood flow outlet; the blood collection device further comprises a wide-body flow guide net, the length and width of the wide-body flow guide net are equal to those of the adsorption films, the adsorption films and the wide-body flow guide net are arranged in an overlapped mode, the core rod serves as a core material to be rolled into a shaft type, the wide-body flow guide net supports the two adjacent layers of adsorption films, gaps are formed between the layers, and blood evenly flows through all the layers of adsorption films through the wide-body flow guide net. The adjacent adsorption films are supported by the wide-body flow guide net, so that the thickness of the blood film guided into the adsorption film winding drum can be reduced, and full contact between blood and the adsorption films is facilitated; the wide-body flow guide net can provide effective support and does not need to be bonded by medical glue, so that the risk of allergic reaction and infection of a patient is reduced; the structure is simple, and industrialization is easy.

Description

Technical Field

[0001] This utility model relates to the field of medical device technology, specifically to an activated leukocyte adsorbent. Background Technology

[0002] Systemic inflammatory response syndrome (SIRS) is a systemic inflammatory response, typically a reaction to infection, trauma, burns, or other serious illness. The presence of SIRS indicates that the body is experiencing a widespread inflammatory response, which can lead to organ dysfunction or failure. If left untreated, SIRS can progress to multiple organ dysfunction syndrome (MODS) or sepsis. Treatment of SIRS usually requires addressing the underlying cause, such as controlling infection, treating trauma or burns, and maintaining hemodynamic stability. In addition, supportive care measures, such as mechanical ventilation, vasoactive drugs, fluid resuscitation, and nutritional support, are also important components of treatment. The prognosis of SIRS depends on its underlying cause and the patient's overall health. Currently, there are no effective treatments; therefore, the advent of activated leukocyte adsorbents (AGIAs) is more advantageous for early intervention and reducing various complications. If the patient's blood is viscous, the conventional arrangement poses a risk of clogging the AGAs; therefore, a new arrangement can increase the permeability of the AGAs.

[0003] Chinese invention patent CN103495218B (authorization announcement date: 2016-10-12) discloses an activated cell adsorber and its control system and control method; Chinese utility model patent CN215821881U (authorization announcement date: 2022-02-15) discloses an activated leukocyte adsorber; and Chinese invention patent CN115518219B (authorization announcement date: 2023-06-16) discloses a low-capacity activated leukocyte adsorber. All of them adopt an adsorption mode instead of a filtration mode. Based on the characteristics of the adsorption membrane material, instead of blood passing through the membrane material, blood flows through the surface of the adsorption membrane. This allows activated leukocytes with adhesive properties to remain on the surface of the adsorption membrane material and be removed, while unactivated leukocytes without adhesive properties remain in the blood, thereby achieving the purpose of selective removal of activated cells. The above patent has the following problems in practical application: (1) The blood film guided into the membrane surface is relatively thick, which is not conducive to the full contact between the blood and the adsorption membrane; (2) The adsorption membrane support structure and the adsorption membrane are bonded with glue, which may cause allergic reactions and infection risks; (3) There is no strong support skeleton in the middle of the adsorption membrane roll, which causes the adsorption membrane to float inside, resulting in poor blood flow performance. Some blood is stuck in the dead corner of the adsorber and cannot flow fully, which may cause thrombosis; (4) The production process is complicated and not easy to mass produce. Utility Model Content

[0004] To address the shortcomings of the existing technology, this invention provides an activated leukocyte adsorbent that is simple in structure and easy to industrialize.

[0005] To achieve the above-mentioned technical objectives, the technical solution adopted by this utility model is as follows:

[0006] An activated leukocyte adsorbent includes an end cap, a shell, an adsorption membrane, and a core rod. The end cap and the shell are connected at both ends to form a closed cavity. The adsorption membrane is located in the closed cavity, and the end caps at both ends are respectively provided with blood flow inlets and outlets. It also includes a wide-body guide net. The length and width dimensions of the wide-body guide net are approximately the same as those of the adsorption membrane. The adsorption membrane and the wide-body guide net are overlapped and rolled into a shaft shape with the core rod as the core material. The wide-body guide net supports two adjacent layers of adsorption membrane and forms gaps between each layer. Blood flows evenly through each layer of adsorption membrane through the wide-body guide net.

[0007] Furthermore, the wide-body flow guide net has two layers, which are respectively located on the upper and lower sides of the adsorption membrane.

[0008] Furthermore, it also includes narrow-body flow guide nets, of which there are two, which are superimposed on both ends of the adsorption membrane.

[0009] Furthermore, the wide-body guide net and the narrow-body guide net are arranged in an interlaced mesh pattern.

[0010] Furthermore, the core rod is formed by two semi-cylinders engaging and connecting to form a cylinder, and one end of the adsorption membrane and the wide-body guide net is clamped between the clamping surfaces of the two semi-cylinders.

[0011] Furthermore, the clamping surfaces of the two semi-cylinders of the mandrel are provided with multiple mutually compatible locking pins and slots along their axial direction.

[0012] Furthermore, the connection between the end cap and the housing is welding, and the welding method is ultrasonic welding.

[0013] Furthermore, the adsorption membrane is an activated leukocyte adsorption membrane, and the material is a polymeric biomaterial.

[0014] The beneficial effects of this utility model are:

[0015] This invention relates to an activated leukocyte adsorbent, which uses a wide-body guide net to support adjacent adsorption membranes. This reduces the thickness of the blood film guiding the blood into the adsorption membrane roll, facilitating full contact between the blood and the adsorption membrane. The wide-body guide net covers the entire adsorption membrane, providing effective support and preventing severe deformation that could lead to poor blood flow. Furthermore, the wide-body guide net and the adsorption membrane do not require medical adhesive for bonding, thus reducing the risk of allergic reactions and infections in patients. In addition, the novel internal structure arrangement of this invention is simple and easy to industrialize.

[0016] The activated leukocyte adsorbent of this invention incorporates narrow strip guide nets at both ends of the adsorption membrane, increasing the permeability of the blood inlet and outlet, allowing the blood to fully contact the adsorption membrane, preventing weakening of blood flow performance, and improving the efficiency of removing activated leukocytes.

[0017] The activated leukocyte adsorbent of this invention uses a core rod made of two semi-cylindrical parts that snap together to hold and fix the adsorption membrane and the wide-body guide net on one side, ensuring reliable fixation and avoiding the use of medical glue. Attached Figure Description

[0018] To more clearly illustrate the technical solutions of the embodiments of this application, the accompanying drawings used in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of this application and should not be regarded as a limitation of the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort.

[0019] Figure 1 This is a schematic diagram of the structure of this utility model;

[0020] Figure 2 This is a schematic diagram of the wide-body airflow guide net structure;

[0021] Figure 3 This is a schematic diagram of the narrow-body guide net structure;

[0022] Figure 4 This is a schematic diagram showing the unfolded arrangement of the adsorption membrane and the flow guiding mesh;

[0023] Figure 5 This is a schematic diagram of the mandrel structure.

[0024] Figure labels: 1-blood inlet / outlet, 2-end cap, 3-shell, 4-wide-body guide net, 5-adsorption membrane, 6-core rod, 7-narrow-body guide net. Detailed Implementation

[0025] To make the objectives, technical solutions, and advantages of the embodiments of this application clearer, the technical solutions of the embodiments of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this application, not all embodiments. The components of the embodiments of this application described and shown in the accompanying drawings can be arranged and designed in various different configurations. Therefore, the following detailed description of the embodiments of this application provided in the accompanying drawings is not intended to limit the scope of the claimed application, but merely represents selected embodiments of this application. All other embodiments obtained by those skilled in the art based on the embodiments of this application without creative effort are within the scope of protection of this application.

[0026] This utility model discloses a novel internal structure arrangement for an activated leukocyte adsorbent, including an end cap 2, a shell 3, a wide-body guide net 4, an adsorption membrane 5, and a core rod 6. The end cap 2 and the shell 3 are connected at both ends to form a closed cavity. The adsorption membrane 5 is located in the closed cavity, and the end caps 2 at both ends are respectively provided with blood flow inlet and outlet 1. The length and width dimensions of the wide-body guide net 4 are similar to those of the adsorption membrane 5. The adsorption membrane 5 and the wide-body guide net 4 are overlapped and rolled into a shaft shape with the core rod 6 as the core material. The wide-body guide net 4 supports two adjacent layers of adsorption membrane and forms gaps between each layer. Blood flows evenly through each layer of adsorption membrane after passing through the wide-body guide net 4.

[0027] Preferably, the wide-body flow guide net 4 has two layers, and the two layers of wide-body flow guide net 4 are respectively disposed on the upper and lower sides of the adsorption membrane 5.

[0028] Furthermore, it also includes a narrow-body guide net 7, of which there are two, which are superimposed on both ends of the adsorption membrane 5, increasing the permeability of the blood inlet and outlet and allowing the blood to come into more full contact with the adsorption membrane.

[0029] The wide-body flow guiding net 4 and the narrow-body flow guiding net 7 are arranged in an interwoven mesh pattern, allowing blood to flow between the mesh gaps. The material is a high-molecular synthetic material. The adsorption membrane 5 is an activated leukocyte adsorption membrane, and its material is a high-molecular biomaterial.

[0030] Furthermore, the core rod 6 is formed by two semi-cylinders engaging to form a cylinder. One side of the adsorption membrane 5, the wide-body guide net 4, and the narrow-body guide net 7 are engaged between the clamping surfaces of the two semi-cylinders. Preferably, the clamping surfaces of the two semi-cylinders have multiple mutually adaptable locking posts and slots along their axial direction in the middle. The locking posts are pressed into the slots to complete the fixation. The connection between the end cap 2 and the shell 3 is welding, specifically ultrasonic welding. The connections between the adsorption membrane 5, the wide-body guide net 4, the narrow-body guide net 7, and the core rod 6 are all compression fittings.

[0031] During use, the activated leukocytes are connected to the patient's extracorporeal circulation tubing. Blood flows in from one end of the blood inlet / outlet 1, passes through the narrow guide net 7 at the inlet end, and then flows into the inside of the adsorption membrane 5 roll. Inside the adsorption membrane 5, the blood flows between two adjacent layers of the adsorption membrane 5. The activated leukocytes are adsorbed by the adsorption membrane 5. The purified blood flows through the narrow guide net 7 at the outlet end of the adsorption membrane, and then flows out through the other end of the blood inlet / outlet 1, returning to the patient's body, thus completing the cycle.

[0032] Of course, there may be other embodiments of this utility model. Without departing from the spirit and essence of this utility model, those skilled in the art can make various corresponding changes and modifications based on this utility model, but these corresponding changes and modifications should all fall within the protection scope of the appended claims of this utility model.

Claims

1. An activated leukocyte adsorbent, comprising end caps (2), a shell (3), an adsorption membrane (5), and a core rod (6), wherein the end caps (2) and the shell (3) are connected at both ends to form a closed cavity, the adsorption membrane (5) is located within the closed cavity, and the end caps (2) at both ends are respectively provided with blood flow inlets and outlets (1); characterized in that, It also includes a wide-body flow guide net (4), the length and width of which are similar to those of the adsorption membrane (5). The adsorption membrane (5) and the wide-body flow guide net (4) are overlapped and rolled into a shaft shape with a core rod (6) as the core material. The wide-body flow guide net (4) supports two adjacent adsorption membranes and forms gaps between each layer. Blood flows evenly through each adsorption membrane layer after passing through the wide-body flow guide net (4).

2. The activated leukocyte adsorbent according to claim 1, characterized in that: The wide-body flow guide net (4) has two layers, and the two layers of wide-body flow guide net (4) are respectively located on the upper and lower sides of the adsorption membrane (5).

3. The activated leukocyte adsorbent according to claim 1 or 2, characterized in that: It also includes a narrow-body flow guide net (7), of which there are two narrow-body flow guide nets (7), which are superimposed on both ends of the adsorption membrane (5).

4. The activated leukocyte adsorbent according to claim 3, characterized in that: The wide-body guide net (4) and narrow-body guide net (7) are arranged in a spaced, interwoven mesh pattern.

5. The activated leukocyte adsorbent according to claim 1, characterized in that: The core rod (6) is formed by two semi-cylinders being snapped together to form a cylinder, and one end of the adsorption membrane (5) and the wide-body guide net (4) is snapped between the clamping surfaces of the two semi-cylinders.

6. The activated leukocyte adsorbent according to claim 4, characterized in that: The clamping surfaces of the two semi-cylinders of the mandrel (6) are provided with a plurality of mutually compatible locking pins and slots along their axial direction.

7. The activated leukocyte adsorbent according to claim 1, characterized in that: The connection between the end cap (2) and the shell (3) is by welding, and the welding method is ultrasonic welding.

8. The activated leukocyte adsorbent according to claim 1, characterized in that: The adsorption membrane (5) is an activated leukocyte adsorption membrane, and the material is a polymer biomaterial.

Images